Key Features
Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreTP53 mutations occur in approximately 50% of all human tumors with increased frequency in aggressive cancers that are notoriously difficult to treat. Additionally, p53 missense mutations are remarkably predictive of refractoriness to chemo/radiotherapy in various malignancies. These observations have led to the development of mutant-p53 targeting agents that restore p53 function. An important unknown is which p53-mutant tumors will respond to p53 reactivation-based therapies. Here we found a heterogeneous impact on therapeutic response to p53 restoration, suggesting it will unlikely be effective as a single therapy.; The goal of the study was to identify the pathways conferring resistance or sensitivity to genetic p53 restoration in tumors with a p53 missense mutaiton; Results:We sequenced the transcriptome of tumors that were sensitive or resistant to p53 restoration and found that TNF signaling was activated in p53-sensitive tumors. SOURCE: Guillermina LozanoDr. Lozano University of Texas MD Anderson Cancer Center
View on GEOView in PlutoEnhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreUse Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.
Read about post-pipeline analysisView quality control data and experiment metadata for this experiment.
Request imports from GEO or TCGA directly within Pluto Bio.
Chat with our Scientific Insights team